Kamada announces expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe. Positive Recommendation by DSMB to Continue the Trial Without Modification. Company is expanding the study to new Europe following the recent moderation of the global COVID-19 pandemic.
🌍 KAMADA (KMDA) - Form 6-K Filing
Filing Date: 2022-05-17
Accepted: 2022-05-17 07:00:25
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: